At a glance
ClinicalIndex Comparison RecordN/ACompleted· 5 enrolled
Drug / intervention
Remote treatment of PCI.device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
CorPath GRX With ReMOTE Proof of Principle (POP): First in Human in India
In Brief
A clinical study evaluating Remote treatment of PCI. for Percutaneous Coronary Intervention. Completed, enrolled 5 participants across 1 site.
Detailed Summary
To evaluate the safety and performance of CorPath GRX POP System, in the ReMOTE (location outside hospital) delivery and manipulation of coronary guidewires and stent/balloon catheters, and manipulation of guide catheters during PCI procedures.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPercutaneous Coronary Intervention
CountriesIndia
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
First PostedOct 2018
Enrollment StartDec 2018
Primary CompletionDec 2018
Study CompletionDec 2018
TodayJul 2026
First PostedOct 15, 2018
Enrollment StartDec 3, 2018
Primary CompletionDec 6, 2018
Study CompletionDec 7, 2018
TodayJul 2, 2026
Enrollment to primary: 3 daysPosted 7.7 years ago
Interventions
Remote treatment of PCI.device
To evaluate the safety and performance of CorPath GRX POP System, in the ReMOTE (location outside hospital) delivery and manipulation of coronary guidewires and stent/balloon catheters, and manipulation of guide catheters during PCI procedures.